VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
CNMD
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
CNMDCONMED Corporation
$51.50$1.5B
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
  1. Home
  2. Financial Ratios

  1. Home
  2. Stocks
  3. CNMD
  4. Financial Ratios

CONMED Corporation (CNMD) Financial Ratios

Latest Ratios: P/E Ratio 21.1x · EV/EBITDA 9.8x · ROE 4.7%. (1996–2025 historical series)

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly

CNMD Valuation Multiples

Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Market Cap$1.5B$1.3B$2.1B$3.5B$2.7B$4.6B$3.3B$3.3B$1.9B$1.4B$1.2B
Enterprise Value$2.3B$2.1B$3.0B$4.4B$3.7B$5.2B$4.0B$4.1B$2.3B$1.9B$1.7B
P/E Ratio →21.1326.8916.0753.68—73.07350.00115.2945.5325.8784.94
P/S Ratio1.130.921.632.782.554.523.833.452.161.801.62
P/B Ratio1.551.222.214.143.575.814.654.642.802.272.13
P/FCF11.628.3813.8432.50229.9447.1364.0543.9431.8727.2352.63
P/OCF9.047.4112.7527.5679.8140.8651.1434.6724.8321.9032.32

P/E links to full P/E history page with 30-year chart

CNMD EV Ratios

Enterprise-value multiples — capital-structure-neutral measures of total business value

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
EV / Revenue—1.502.303.553.535.184.694.262.672.372.22
EV / EBITDA9.799.5611.9625.7126.4328.9934.1326.8517.2417.9118.24
EV / EBIT16.5620.1415.0336.66—48.1788.6955.0032.1740.2648.83
EV / FCF—13.6419.5641.59318.5353.9878.6054.1639.4235.8472.27

CNMD Profitability

Margins and return-on-capital ratios measuring operating efficiency

Margins

Full margin charts and quarterly trend are on the Earnings History page

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Gross Margin52.8%52.8%56.1%54.3%54.6%56.2%53.4%54.9%54.6%54.1%53.5%
Operating Margin10.3%10.3%15.3%9.7%6.7%10.9%5.3%8.3%8.3%5.9%4.9%
Net Profit Margin3.4%3.4%10.1%5.2%-7.7%6.2%1.1%3.0%4.8%7.0%1.9%

Return on Capital

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
ROE4.7%4.7%14.7%8.2%-10.5%8.4%1.3%4.2%6.3%9.2%2.5%
ROA2.0%2.0%5.7%2.8%-4.0%3.6%0.5%1.8%3.0%4.1%1.2%
ROIC5.8%5.8%8.2%5.1%3.3%5.7%2.4%4.6%4.9%3.3%3.1%
ROCE7.0%7.0%10.0%6.0%3.9%7.0%2.9%5.7%5.9%3.9%3.4%

CNMD Leverage & Debt

Solvency and debt-coverage ratios — lower is generally safer

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Debt / Equity0.810.810.941.191.410.871.101.120.690.770.84
Debt / EBITDA3.883.883.605.767.563.796.545.243.434.615.25
Net Debt / Equity—0.770.921.161.380.851.061.080.660.720.79
Net Debt / EBITDA3.693.693.505.627.353.686.315.073.304.304.96
Debt / FCF—5.265.739.1088.596.8514.5410.227.558.6119.64
Interest Coverage3.293.295.373.03-1.453.061.041.733.452.582.26

CNMD Liquidity & Efficiency

Short-term solvency ratios and asset-utilisation metrics

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Current Ratio2.142.142.301.981.962.342.192.112.332.382.90
Quick Ratio1.011.011.050.960.841.161.171.241.371.441.71
Cash Ratio0.130.130.090.080.100.110.140.140.110.220.24
Asset Turnover—0.590.570.540.460.570.490.540.630.590.57
Inventory Turnover1.831.831.661.791.431.912.062.612.532.582.61
Days Sales Outstanding—65.8166.3971.0466.8066.4174.9772.2777.0976.5670.87

CNMD Shareholder Yields

Earnings, FCF, buyback, and dividend yields — total returns to shareholders

Dividends

Full dividend history and growth charts are on the Dividend History page

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Dividend Yield1.5%2.0%1.2%0.7%0.9%0.5%0.7%0.7%1.2%1.6%1.8%
Payout Ratio52.6%52.6%18.6%38.0%—37.2%239.8%79.0%54.9%40.2%151.5%

Total Shareholder Return Metrics

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Earnings Yield4.7%3.7%6.2%1.9%—1.4%0.3%0.9%2.2%3.9%1.2%
FCF Yield8.6%11.9%7.2%3.1%0.4%2.1%1.6%2.3%3.1%3.7%1.9%
Buyback Yield0.0%0.0%0.0%0.0%2.7%0.0%0.0%0.9%0.0%0.0%0.0%
Total Shareholder Yield1.5%2.0%1.2%0.7%3.6%0.5%0.7%1.6%1.2%1.6%1.8%
Shares Outstanding—$31M$31M$32M$30M$32M$29M$29M$29M$28M$28M

Key Metrics

Growth RegimeStable
ProfitabilityModerate
Balance SheetAdequate
Cash FlowMixed
Top Statement Risk

Thin cash buffer against leverage

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q3)

Trailing Multiple Overstates Cost Versus Forward Earnings

Based on the supplied figures, CNMD trades at 34.1x trailing P/E but only 11.3x forward P/E, a gap suggesting reported earnings are depressed by volatile quarterly items rather than reflecting a structurally expensive stock.

The spread between trailing and forward earnings multiples implies the market expects normalization of the earnings swings seen across the last ten quarters, where net margin ranged from 0.8% to 15.5%. A forward EV/EBITDA of 8.6x against a trailing 12.1x points the same direction. Investors should treat the forward multiple as conditional on margin recovery, since the PEG of 0.94 only looks attractive if expected growth materializes given flat recent revenue.

Operating Margin Volatility Obscures Earning Power

According to the reported quarterly figures, CNMD's operating margin swung between 3.6% and 20.7% over the period, with 2026Q3 at 11.1%, indicating that no single quarter reliably represents the company's underlying earning power.

Gross margin has held in a relatively stable 56% to 58% band for most recent quarters, which suggests pricing and product mix are not the primary source of the swings. The variability instead appears to sit in operating expense absorption, implying a normalized operating margin should be estimated across a full cycle rather than read from any single period. Net margin dispersion is wider still, which warrants investigation into non-operating and tax items before capitalizing current earnings.

Returns Decaying Below Historical Peak Levels

Based on reported figures, CNMD's ROIC declined from 2.7% in late 2024 to a range of 0.5% to 2.7% through 2026, while ROE fell from a 5.4% peak to 1.3% in 2026Q1, suggesting returns on capital have not recovered.

Returns sit well below what a company with 56% gross margins would typically generate, pointing to heavy capital intensity or a large asset base diluting profit. Goodwill of $796.9M, roughly 35% of total assets, may depress ROIC by inflating invested capital, which could explain part of the gap versus peers. Investors should assess whether returns are structurally capped or cyclically depressed before assuming a rebound.

Deleveraging Progress Constrained by Coverage

As reported in financial statements, CNMD reduced its D/E from 1.10 to 0.77 over the period, yet interest coverage remained volatile between 1.56x and 7.10x, leaving debt service comfort dependent on the quarter.

Debt fell from $965.9M to $815.9M while equity rose, so the leverage improvement is real but driven partly by retained earnings rather than cash generation alone. Debt-to-EBITDA ratios near 14x to 36x in several quarters suggest the earnings base used to service debt is thin in weaker periods. Refinancing risk cannot be assessed from the supplied data, and investors should monitor coverage trends closely.

Goodwill and Trailing Earnings Distort the Picture

Based on the supplied peer table, CNMD's 8.4% net margin and 9.7% ROIC are not far from MMSI and HOLX, but trail LMAT's 23.1% net margin and 9.7% ROIC on a cash-adjusted basis, with a 0.77 D/E sitting above most peers.

The misapplied metric here is trailing P/E, which is distorted by volatile quarterly net income and the amortization burden tied to $796.9M of goodwill. An EV/EBITDA or free-cash-flow-yield lens, adjusted for acquisition-related amortization, would better reflect earning power. CNMD's gross margin is competitive, so the gap appears to sit below the gross line, consistent with higher operating overhead relative to LMAT; whether this is structural or temporary depends on SG&A intensity, which the supplied data does not confirm.

Download Financial Ratios Data

Includes 30+ ratios · 30 years · Updated daily

Consensus & Technical Research Suite
Open CNMD Terminal

CNMD Chart Terminal

WASM

Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.

Launch Terminal

Live Breakouts Feed

LIVE

High-probability breakout stocks crossing their pivot across 5 pattern engines.

Explore Setups

Intrinsic Valuation

DCF models, multiple analysis, and analyst estimates.

Check Valuation

Historical Returns

10-year return with dividends reinvested.

Calculate

Peer Comparison

Compare growth, multiples, and margins vs sector.

Compare

CNMD — Frequently Asked Questions

Quick answers to the most common questions about buying CNMD stock.

What is CONMED Corporation's P/E ratio?

CONMED Corporation's current P/E ratio is 21.1x. The historical average is 32.8x. This places it at the 40th percentile of its historical range.

What is CONMED Corporation's EV/EBITDA?

CONMED Corporation's current EV/EBITDA is 9.8x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 14.7x.

What is CONMED Corporation's ROE?

CONMED Corporation's return on equity (ROE) is 4.7%. The historical average is 6.0%.

Is CNMD stock overvalued?

Based on historical data, CONMED Corporation is trading at a P/E of 21.1x. This is at the 40th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.

What is CONMED Corporation's dividend yield?

CONMED Corporation's current dividend yield is 1.54% with a payout ratio of 52.6%.

What are CONMED Corporation's profit margins?

CONMED Corporation has 52.8% gross margin and 10.3% operating margin. Operating margin between 10-20% is typical for established companies.

How much debt does CONMED Corporation have?

CONMED Corporation's Debt/EBITDA ratio is 3.9x, indicating high leverage. A ratio between 2-4x is manageable but warrants monitoring.